REGULATORY

Safety-Related Label Revision Ordered for Trulicity, CP Inhibitors, and More

March 6, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) on March 5 ordered label revisions to flag new safety risks for a batch of medicines on the market including Eli Lilly’s GLP-1 receptor agonist Trulicity (dulaglutide). According to the MHLW’s notification…

To read the full story

PMDA Reviewing Safety Risks for Immune Checkpoint Inhibitors, CAR-Ts
February 10, 2025

REGULATORY

Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…